|
|
Intratumoral
LAK cell and interleukin-2 therapy of human gliomas
Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH
Clinical Neurosurgery Section, National Institute of Neurological
and Communicative Disorders and Stroke, Bethesda, Maryland.
Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and
interleukin-2 (IL-2) offers the possibility of a new treatment for patients with
malignant glial tumors.
In a clinical trial, the effectiveness of a 5-day treatment cycle of direct
intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter
system in patients with recurrent malignant gliomas was studied.
Ten patients were entered into the study, nine of whom were treated with 15
cycles of LAK cells (0.9 to 21.0 x 10(9) cells) and IL-2 (49 to 450 x 10(3)
U/kg).
The 10th patient in the study was not treated because of the onset of severe
neurological deficits prior to beginning immunotherapy.
Of the nine patients treated, one had a partial tumor response to immunotherapy
as documented by computerized tomography.
Neurological side effects occurred in all patients undergoing treatment and were
related to increases in cerebral edema that appeared to be mediated by the
immunotherapy.
This report demonstrates the present limitations of regional adoptive
immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.
PMID:
2643685 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2643685&dopt=Abstract
|
